Petr Zatloukal

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Journal of Clinical Oncology · 2009 · 1.5K citations

Medicine, Oncology, Pharmacology +13

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Martin Reck, Joachim von Pawel, Petr Zatloukal et al. · Annals of Oncology · 2010 · 644 citations · Full text

Medicine, Oncology, Pharmacology +11

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

Petr Zatloukal, Luboš Petruželka, Milada Zemanová et al. · Lung Cancer · 2004 · 431 citations

Medicine, Oncology, Radiation Oncology +12

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Bohuslav Melichar, Antoine Adenis, A. Craig Lockhart et al. · The Lancet Oncology · 2015 · 251 citations

Medicine, Oncology, Pharmacology +15

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

Giuseppe Giaccone, Petr Zatloukal, Jaromı́r Roubec et al. · Journal of Clinical Oncology · 2009 · 245 citations

Medicine, Oncology, Pharmacology +15